Q2 FY26 Results: Profit boosted by one-time Ebix settlement gain

Emphasis of matterResults restatedRelated-party transactionsExceptional itemProfit growth above 25%Contingent liabilities increasedResults View source PDF Explain this filing

VIKASLIFE · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

+0.0%Reaction day

₹1.65

prior close

₹1.68

announcement price

After-mkt

timing

Nifty Microcap 250market · in no size index; the smallest one is used+1.3%-1.3% vs market

Trading & Distributors peers, median of 134sector+0.1%-0.1% vs sector

On the reaction day the stock moved 1.3 pts less than Nifty Microcap 250 and 0.1 pts less than its Trading & Distributors peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

-3.6

10m

-1.8

15m

-3.6

30m

-4.2

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

+0.0+1.3-1.3+0.1-0.1

Next day

-0.6+1.1-1.7+0.0-0.6

-3.0-0.4-2.7-0.4-2.6

-2.4+2.0-4.5-0.4-2.1

-3.0+1.9-4.9-1.0-2.0

-3.6+1.9-5.5-0.7-2.9

-4.8+3.0-7.8-1.9-2.9

15d

-7.3+2.3-9.6-3.3-3.9

-12.1+2.8-15.0-4.6-7.5

-9.7+11.9-21.6-5.4-4.3

-20.6+10.5-31.1-10.8-9.8

UpDownMarket · Nifty Microcap 250Sector · Trading & Distributors peers, median of 134Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Vikas Lifecare reported H1 FY26 revenue of ₹229.67 cr (up ~3.5% YoY). Net profit surged to ₹124.15 cr from ₹1.99 cr, driven mainly by a one-time ~₹130 cr gain from receiving 51% equity in Ebix International Holdings (UK) via settlement. Q1 FY26 results were restated. Auditor flagged multiple emphasis-of-matter items: pending shareholder approval for related party transactions, pending IGTL share transfer approvals, and unevaluated tax implications of the settlement. Board also approved seeking shareholder consent via postal ballot addendum for RPTs.

Likely market impact

Headline profit masks weak core operations; one-time Ebix gain is not recurring. Auditor flags on RPT approvals, pending compliances, and tax uncertainty warrant caution.